Stenzl - Figure 34
Monitoring of systemic therapy for metastatic urothelial cancer?
FIG. 34: Another possibility of clinical application of molecular subtyping could be the monitoring of systemic therapy for metastatic urothelial cancer, in order to know how well a patient is responding and how many cycles the patient will need. For example, it might be that the patient should switch to another form of systemic therapy or perhaps that a more intensive number of cycles is needed – all of which varies on an individual basis.
